SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 3, 2015) - Titan Pharmaceuticals, Inc. (
Mr. Bhonsle will review Titan's development program for Probuphine® for the long-term maintenance treatment of opioid dependence, including the recent resubmission of the New Drug Application (NDA) for Probuphine to the U.S. Food and Drug Administration. He will also provide an overview of the company's ProNeura™ for Parkinson's disease program and other upcoming milestones for 2015.
About Titan Pharmaceuticals
Titan Pharmaceuticals Inc. (
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT: Titan Pharmaceuticals, Inc. President Sunil Bhonsle (650) 244-4990 Investors: Stephen Kilmer (647) 872-4849 skilmer@titanpharm.com Media: Susan Thomas (619) 540-9195 sthomas@titanpharm.com